Maravai LifeSciences Holdings, Inc.
MRVI
$7.38
$0.081.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.53% | 40.53% | -11.83% | -39.69% | -31.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.53% | 40.53% | -11.83% | -39.69% | -31.73% |
| Cost of Revenue | -22.30% | -17.86% | -4.96% | -2.22% | 2.71% |
| Gross Profit | 165.83% | 336.26% | -25.00% | -82.46% | -74.81% |
| SG&A Expenses | -14.85% | -26.47% | -26.33% | -9.44% | -7.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.00% | -22.09% | -16.24% | -6.66% | -2.25% |
| Operating Income | 56.52% | 101.96% | 25.69% | -190.60% | -137.56% |
| Income Before Tax | 70.59% | 87.61% | -36.76% | 73.77% | -255.43% |
| Income Tax Expenses | 96.01% | -193.21% | 185.71% | -129.58% | -76.10% |
| Earnings from Continuing Operations | 69.03% | 87.93% | -36.79% | 73.87% | -279.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -69.53% | -88.46% | 35.57% | -74.13% | 250.43% |
| Net Income | 68.64% | 87.53% | -37.74% | 73.67% | -304.44% |
| EBIT | 56.52% | 101.96% | 25.69% | -190.60% | -137.56% |
| EBITDA | 84.55% | 150.37% | 48.85% | -5,497.09% | -876.51% |
| EPS Basic | 69.44% | 87.79% | -34.65% | 74.25% | -280.72% |
| Normalized Basic EPS | -168.80% | 115.92% | 2,855.17% | -106.21% | 165.96% |
| EPS Diluted | 69.44% | 87.79% | -34.65% | 74.25% | -280.72% |
| Normalized Diluted EPS | -168.80% | 115.92% | 2,855.17% | -106.21% | 165.96% |
| Average Basic Shares Outstanding | 2.61% | 2.09% | 2.30% | 2.21% | 6.18% |
| Average Diluted Shares Outstanding | 2.61% | 2.09% | 2.30% | 2.21% | 6.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |